NYSE:HQL

Tekla Life Sciences Investors Stock Forecast, Price & News

$21.32
-0.43 (-1.98 %)
(As of 09/20/2021 04:00 PM ET)
Add
Compare
Today's Range
$21.10
$21.66
50-Day Range
$20.27
$22.67
52-Week Range
$16.60
$22.70
Volume76,242 shs
Average Volume78,432 shs
Market Capitalization$517.63 million
P/E RatioN/A
Dividend Yield7.68%
Beta0.94
30 days | 90 days | 365 days | Advanced Chart
Receive HQL News and Ratings via Email

Sign-up to receive the latest news and ratings for Tekla Life Sciences Investors and its competitors with MarketBeat's FREE daily newsletter.


Tekla Life Sciences Investors logo

About Tekla Life Sciences Investors

Tekla Life Sciences Investors operates as a closed-end investment fund or Investment trust. The firm engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services. The company was founded on February 20, 1992 and is headquartered in Boston, MA.

Headlines

Tekla Life Sciences Investors (NYSE:HQL) Short Interest Update
Tekla Life Sciences Investors (NYSE:HQL) Short Interest Update
August 26, 2021 |  americanbankingnews.com
5 Dividend Funds Yielding Up To 27.2%
5 Dividend Funds Yielding Up To 27.2%
August 15, 2021 |  forbes.com
Tekla Life Sciences Investors Declares Cash Distribution
Tekla Life Sciences Investors Declares Cash Distribution
December 21, 2020 |  finance.yahoo.com
Understanding Tekla Life Sciencess Ex-Dividend Date
Understanding Tekla Life Sciences's Ex-Dividend Date
November 24, 2020 |  benzinga.com
Tekla Life Sciences Investors Declares Distribution
Tekla Life Sciences Investors Declares Distribution
November 16, 2020 |  finance.yahoo.com
HQH: Deep Discount Leads To High Yield
HQH: Deep Discount Leads To High Yield
November 9, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.74 out of 5 stars

Finance Sector

842nd out of 1,332 stocks

Investment Offices, Not Elsewhere Classified Industry

13th out of 156 stocks

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Tekla Life Sciences Investors (NYSE:HQL) Frequently Asked Questions

What stocks does MarketBeat like better than Tekla Life Sciences Investors?

Wall Street analysts have given Tekla Life Sciences Investors a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tekla Life Sciences Investors wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tekla Life Sciences Investors?

Tekla Life Sciences Investors saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 26,900 shares, a decrease of 40.5% from the August 15th total of 45,200 shares. Based on an average trading volume of 67,600 shares, the short-interest ratio is currently 0.4 days.
View Tekla Life Sciences Investors' Short Interest
.

How has Tekla Life Sciences Investors' stock been impacted by Coronavirus (COVID-19)?

Tekla Life Sciences Investors' stock was trading at $14.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HQL stock has increased by 43.6% and is now trading at $21.32.
View which stocks have been most impacted by COVID-19
.

How often does Tekla Life Sciences Investors pay dividends? What is the dividend yield for Tekla Life Sciences Investors?

Tekla Life Sciences Investors declared a quarterly dividend on Wednesday, August 18th. Shareholders of record on Friday, August 27th will be given a dividend of $0.43 per share on Thursday, September 30th. This represents a $1.72 dividend on an annualized basis and a yield of 8.07%. The ex-dividend date is Thursday, August 26th. This is an increase from Tekla Life Sciences Investors's previous quarterly dividend of $0.41.
View Tekla Life Sciences Investors' dividend history
.

Is Tekla Life Sciences Investors a good dividend stock?

Tekla Life Sciences Investors pays an annual dividend of $1.67 per share and currently has a dividend yield of 7.68%. HQL has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
View Tekla Life Sciences Investors' dividend history.

Who are Tekla Life Sciences Investors' key executives?

Tekla Life Sciences Investors' management team includes the following people:
  • Dan Omstead, President, Chief Executive Officer & Trustee
  • Jason C. Akus, Senior Vice President-Research
  • Timothy L. Gasperoni, Senior Vice President-Research
  • Laura F. Woodward, Secretary, Treasurer & Chief Compliance Officer

Who are some of Tekla Life Sciences Investors' key competitors?

What other stocks do shareholders of Tekla Life Sciences Investors own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tekla Life Sciences Investors investors own include NVIDIA (NVDA), Energy Transfer (ET), QUALCOMM (QCOM), AT&T (T), Enbridge (ENB), International Business Machines (IBM), Kinder Morgan (KMI), Main Street Capital (MAIN), Pfizer (PFE) and Weyerhaeuser (WY).

What is Tekla Life Sciences Investors' stock symbol?

Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL."

Who are Tekla Life Sciences Investors' major shareholders?

Tekla Life Sciences Investors' stock is owned by many different retail and institutional investors. Top institutional shareholders include Advisors Asset Management Inc. (1.80%), Morgan Stanley (1.74%), Morgan Stanley (1.74%), Wells Fargo & Company MN (1.35%), Matisse Capital (0.68%) and Advisor Group Holdings Inc. (0.55%).
View institutional ownership trends for Tekla Life Sciences Investors
.

Which institutional investors are selling Tekla Life Sciences Investors stock?

HQL stock was sold by a variety of institutional investors in the last quarter, including 1832 Asset Management L.P., 1832 Asset Management L.P., Matisse Capital, Wells Fargo & Company MN, 1607 Capital Partners LLC, Citigroup Inc., Invesco Ltd., and Advisor Group Holdings Inc..
View insider buying and selling activity for Tekla Life Sciences Investors
or view top insider-selling stocks.

Which institutional investors are buying Tekla Life Sciences Investors stock?

HQL stock was bought by a variety of institutional investors in the last quarter, including Stephens Inc. AR, Shaker Financial Services LLC, Morgan Stanley, Morgan Stanley, Advisors Asset Management Inc., Kingsview Wealth Management LLC, Cambridge Investment Research Advisors Inc., and Mid Atlantic Financial Management Inc. ADV.
View insider buying and selling activity for Tekla Life Sciences Investors
or or view top insider-buying stocks.

How do I buy shares of Tekla Life Sciences Investors?

Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tekla Life Sciences Investors' stock price today?

One share of HQL stock can currently be purchased for approximately $21.32.

How much money does Tekla Life Sciences Investors make?

Tekla Life Sciences Investors has a market capitalization of $517.63 million.

What is Tekla Life Sciences Investors' official website?

The official website for Tekla Life Sciences Investors is www.teklacap.com.

Where are Tekla Life Sciences Investors' headquarters?

Tekla Life Sciences Investors is headquartered at 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109.

How can I contact Tekla Life Sciences Investors?

Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at (617) 772-8500 or via email at [email protected].


This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.